Showing 4461-4470 of 7117 results for "".
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Paratek: Phase 3 Data Show Omadacycline Effective Against Common Skin Pathogens, Including MRSAhttps://practicaldermatology.com/news/paratek-phase-3-data-show-omadacycline-effective-against-common-skin-pathogens-including-mrsa/2458211/Analysis of microbiology data from a Phase 3 study of omadacycline in acute skin infections shows that once-daily treatment with IV-to-oral omadacycline is effective in treating the most frequently isolated bacterial pathogens associated with skin infections, including methicillin-resistant S
- EWG Surveys Personal Care Product Companies About Removing 1,4-Dioxanehttps://practicaldermatology.com/news/ewg-surveys-personal-care-product-companies-about-removing-14-dioxane/2458220/The Environmental Working Group (EWG) is surveying U.S. makers of personal care products to ask if they are working to remove 1,4-dioxane, a potential human carcinogen, from their products. At least 8,000 products on the market contain ethoxylated ingredie
- Business News: Allergan and ZELTIQ Announce Expiration of HSR Waiting Period for Pending Transactionhttps://practicaldermatology.com/news/business-news-allergan-and-zeltiq-announce-expiration-of-hsr-waiting-period-for-pending-transaction/2458225/Allergan is now one step closer to officially acquiring Zeltiq. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") has expired with respect to Allergan's proposed acquisition of ZELTIQ.
- Dr. George J. Hruza Elected AAD President-Electhttps://practicaldermatology.com/news/dr-george-j-hruza-elected-aad-president-elect/2458231/George J. Hruza, MD, MBA, FAAD, has been elected president-elect of the American Academy of Dermatology (AAD). Dr. Hruza also will hold this position for the American Academy of Dermatology Association. He will be installed as president-elect in February 2018 and hold the office of president for
- FDA Approves New Eczema Drug Dupixenthttps://practicaldermatology.com/news/fda-approves-new-eczema-drug-dupixent/2458233/The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are n
- No Antibiotics Needed For Mild Infected Eczema in Kidshttps://practicaldermatology.com/news/no-antibiotics-needed-for-mild-infected-eczema-in-kids/2458238/Oral or topical antibiotics are not effective for treating milder clinically infected eczema in children, a new study shows. In the study of 113 children with clinical, non-severely infected eczema, participants received either oral
- Education Credits Available: ABCs of Nitric Oxide in the Skinhttps://practicaldermatology.com/news/education-credits-available-abcs-of-nitric-oxide-in-the-skin/2458239/A free, online educational program intended to provide participants increased knowledge regarding the role of NO in maintaining a variety of physiologic processes has been launched. The program is directed by James Q. Del Rosso, DO. The program is also intended to address the correlation of